Visual Recovery with Iloprost Added to Corticosteroids in a Case of Giant Cell Arteritis

Ocul Immunol Inflamm. 2022 Feb 17;30(2):497-499. doi: 10.1080/09273948.2020.1802489. Epub 2020 Sep 25.

Abstract

Introduction: To date, corticosteroids remain the cornerstone treatment of ocular involvement of GCA, and no other treatment has proven to be effective in this setting. We herein report on a unique case of GCA with ocular involvement worsening despite high dose corticosteroids and recovering with intravenous iloprost.

Case report: A 70-year-old man presented with acute vision loss in his left eye related to anterior ischemic optic neuropathy. The diagnosis of giant-cell arteritis was confirmed by a temporal artery biopsy. Despite intravenous pulse methylprednisolone for 3 days then oral prednisone at 60 mg/day, the patient developed from day 5 fluctuating vision loss in the right eye, related to ocular ischemia by occlusion of the ophthalmic artery, and responsive to hyperhydration. Iloprost, an analog of prostacyclin PGI2, was then administered intravenously for 5 days and resulted in a stable improvement in visual acuity in the right eye.

Conclusion: This case highlights the potential role of vasodilatator agents in giant cell arteritis with ocular involvement.

Keywords: Giant cell arteritis; anterior ischemic optic neuropathy; corticosteroids; iloprost; ocular complications.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Aged
  • Giant Cell Arteritis* / diagnosis
  • Giant Cell Arteritis* / drug therapy
  • Humans
  • Iloprost / therapeutic use
  • Male
  • Optic Neuropathy, Ischemic* / diagnosis
  • Optic Neuropathy, Ischemic* / drug therapy
  • Optic Neuropathy, Ischemic* / etiology
  • Temporal Arteries / pathology

Substances

  • Adrenal Cortex Hormones
  • Iloprost